Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

New antibody drug shows positive results for treating Crohn's disease, ulcerative colitis

Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn's disease and ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The findings, published in two papers, will appear in the August 22 issue of the New England Journal of Medicine (NEJM).

22 Aug 2013

Caltech biologists identify mechanism by which beneficial bacteria reside, thrive in gastrointestinal tract

The human body is full of tiny microorganisms-hundreds to thousands of species of bacteria collectively called the microbiome, which are believed to contribute to a healthy existence. The gastrointestinal (GI) tract-and the colon in particular-is home to the largest concentration and highest diversity of bacterial species.

20 Aug 2013

Risk of infectious gastroenteritis and IBD relapse increases during heat wave periods

Swiss researchers report an increase risk of inflammatory bowel disease (IBD) relapse in patients during heat wave periods. The study published in The American Journal of Gastroenterology also found an increase of infectious gastroenteritis during heat waves, with the strongest impact following a 7 day lag time after the heat wave.

14 Aug 2013

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

BioLineRx, a biopharmaceutical development company, announced today that BL-8040 has been shown in pre-clinical trials to be effective for the treatment of thrombocytopenia, or reduced platelet production.

5 Aug 2013

Researchers discover mechanism that prevents immune system from spinning out of control

A team led by a University of Arizona researcher has discovered a previously unknown mechanism that prevents the immune system from going into overdrive, shedding light not only on how our body controls its response to pathogens but on conditions such as autoimmune diseases, allergies and chronic inflammation as well.

24 Jul 2013

Study shows environmental conditions have stronger influence on human microbiome

Environmental conditions have a much stronger influence on the mix of microbes living in various parts of your body than does competition between species. Instead of excluding each other, microbes that fiercely compete for similar resources are more likely to cohabit the same individual.

17 Jul 2013

Researcher receives $1.58M NIDCR grant to advance research on link between oral bacteria and fetal death

A new four-year, $1.58 million grant from the National Institute of Dental and Craniofacial Research, will allow a Case Western Reserve University School of Dental Medicine researcher to advance her work linking oral bacteria to fetal death.

9 Jul 2013

VBL Therapeutics publishes VB-201 pre-clinical data in journal of Atherosclerosis

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, announced today the publication of pre-clinical data for VB-201 in the journal of Atherosclerosis.

8 Jul 2013

Nearly half a million dollars given to physicians working to cure psoriatic diseases

Twelve residents and medical students each received a one-year, $40,000 National Psoriasis Foundation fellowship to study psoriasis and psoriatic arthritis.

3 Jul 2013

Study reveals circadian disruption is a risk factor in alcoholic liver disease

Thirty percent of severe alcoholics develop liver disease, but scientists have not been able to explain why only a subset is at risk. A research team from Northwestern University and Rush University Medical Center now has a possible explanation: disrupted sleep and circadian rhythms can push those vulnerable over the edge to disease.

2 Jul 2013

Study reports new mechanism that regulates specification of lymphocytes

Scientists at an Academy of Finland Centre of Excellence have discovered a new mechanism regulating the immune response that can leave a person susceptible to autoimmune diseases.

28 Jun 2013

Hospira receives positive opinion from EMA's CHMP for EC approval of Inflectra

Hospira, the world's leading provider of injectable drugs and infusion technologies, today received a positive opinion from the European Medicines Agency Committee for Medicinal Products for Human Use, recommending the European Commission approval of Inflectra (infliximab) for rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis.

28 Jun 2013

Janssen, Johnson & Johnson Innovation establish IBD research alliance with Mount Sinai

Janssen Biotech, Inc. and Johnson & Johnson Innovation announced today the establishment of a research alliance with The Icahn School of Medicine at Mount Sinai to advance the scientific understanding of inflammatory bowel disease and the discovery of next generation therapeutic solutions.

27 Jun 2013

Reason for large increase in hospitalizations of children with IBD unclear, researchers report

The largest investigation to date has found a dramatic increase in the number of hospitalizations for children with inflammatory bowel disease during the past decade in the United States.

26 Jun 2013

Shield Therapeutics recruits patients for ST10 Phase 3 study for treating iron-deficient anaemia

Shield Therapeutics, the independent specialty mineral medicines pharmaceutical company, today announces that it has completed recruitment of patients into its pivotal Phase 3 programme of ST10 for the treatment of iron-deficient anaemia. ST10 is a novel form of ferric iron taken orally.

24 Jun 2013

Cedars-Sinai Graduate Program to award diplomas to six students

The Cedars-Sinai Graduate Program in Biomedical Sciences and Translational Medicine will award its first diplomas to six students during a commencement ceremony June 11.

11 Jun 2013

BioLineRx signs out-licensing agreement with CTTQ to develop, commercialize Hepatitis C drug

BioLineRx, a biopharmaceutical development company, announced today that it has signed an out-licensing agreement with Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., the leading Chinese pharmaceutical company in the liver disease therapeutic area, for the development and commercialization of BL-8030, an orally available treatment for the Hepatitis C virus.

10 Jun 2013

Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

New antibody drug shows positive results for treating Crohn's disease, ulcerative colitis

Caltech biologists identify mechanism by which beneficial bacteria reside, thrive in gastrointestinal tract

Risk of infectious gastroenteritis and IBD relapse increases during heat wave periods

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

Researchers discover mechanism that prevents immune system from spinning out of control

Study shows environmental conditions have stronger influence on human microbiome

Researcher receives $1.58M NIDCR grant to advance research on link between oral bacteria and fetal death

VBL Therapeutics publishes VB-201 pre-clinical data in journal of Atherosclerosis

Nearly half a million dollars given to physicians working to cure psoriatic diseases

Study reveals circadian disruption is a risk factor in alcoholic liver disease

Study reports new mechanism that regulates specification of lymphocytes

Hospira receives positive opinion from EMA's CHMP for EC approval of Inflectra

Janssen, Johnson & Johnson Innovation establish IBD research alliance with Mount Sinai

Reason for large increase in hospitalizations of children with IBD unclear, researchers report

Shield Therapeutics recruits patients for ST10 Phase 3 study for treating iron-deficient anaemia

Cedars-Sinai Graduate Program to award diplomas to six students

BioLineRx signs out-licensing agreement with CTTQ to develop, commercialize Hepatitis C drug

BioLineRx starts enrollment in Phase 2 trial of BL-8040 for treatment of AML

Scientists discover protective role of retinoic acid against intestinal inflammation

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in